WHI-P180 is primarily used in biomedical research as a selective inhibitor of the Janus kinase (JAK) signaling pathway, particularly targeting JAK3. It is employed to study immune cell signaling and inflammation processes. Due to its specificity, it helps researchers dissect the role of JAK3 in cytokine receptor signaling, especially in lymphocyte activation and proliferation. WHI-P180 has been utilized in experimental models to explore potential therapeutic strategies for autoimmune diseases and transplant rejection. Its application also extends to cancer research, where modulation of JAK-STAT pathways can influence tumor growth and immune evasion.